Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors

Abstract

In prostate cancer, sensitivity to PARPi is dependent on the specific type and zygosity of the CDK12 mutation. PARPi monotherapy may have some activity in patients with prostate cancer with biallelic inactivating CDK12 alterations.